News About SaNOtize Nasal Spray (Enovid)

Gilly Regev and Chris Miller write about The Power of Nitric Oxide on MedCityNews.com

On January 23, 2023 0 Comment

"The Power of NO: How a Tiny Natural Molecule Can Help Shift How We Treat Covid-19 and Other Infections While more work needs to be done, the current research into new delivery platforms for nitric oxide is extremely promising. We hope to see the molecule play an increasingly prominent role in treatment and prevention strategies for common infections – and in so doing help provide greater access to healthcare globally." Published on Jan 4th, 2023 on MedCityNews.com, By Gilly Regev and Chris Miller Click here to read the full article

The Jerusalem Post: Can an anti-viral nasal spray stop Corona and other viruses?

On January 23, 2023 0 Comment

"Enovid, an innovative anti-viral spray developed in Canada by an Israeli researcher and manufactured in Israel, has been proven effective in preventing viruses – including COVID-19 – from entering the body through the nasal cavity." Published: JANUARY 3, 2023 12:13 on the Jerusalem post, click to READ MORE

SaNOtize moves to carve a new market demand: over-the-counter prevention

On September 22, 2022 0 Comment

There are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian biotech SaNOtize wants to change that, charting plans to move a nasal spray into a phase 3 study as soon as October. It’s a deviation for the company that until now has been developing the nitric oxide nasal spray (NONS) as an early antiviral treatment, primarily assessing a reduction in viral load and testing time. But the takeaway from the company’s July 18 meeting with regulators was that those two markers wouldn’t be sufficient primary endpoints in a phase 3 treatment trial over a reduction...

SaNOtize raised $24M to fund phase 3 trial of COVID-19 nasal spray

On September 22, 2022 0 Comment

SaNOtize has raised a $24 million series B round, giving it the cash to fund its ongoing phase 3 COVID-19 prevention trial and other research into its nitric oxide nasal spray (NONS). The Vancouver-based company set up shop in 2017 to unlock the antimicrobial properties of nitric oxide. Using its nitric oxide releasing solution platform, SaNOtize sought to enable the use of the molecule in sprays, baths, lavages, gels and creams. Interest in the platform went up a gear in 2020 when COVID-19 created a pressing need for interventions capable of treating and preventing SARS-CoV-2 infection. Published by Nick Paul Taylor on Aug...

Clinical Study Suggests SaNOtize Nitric Oxide Nasal Spray Is Effective at Preventing COVID-19 after High-Risk Exposure

On May 31, 2022 0 Comment

Published on May 11, 2022 on Businesswire.com. After confirmed exposure to COVID-19, infection rate in participants (n=625) who took NONS™ was 6.4% versus 25.6% in the control group (P<0.0001). The new data build upon previously reported Phase III trial results demonstrating that a rapid reduction of viral load prevents progression to infection after COVID-19 exposure. The new study, conducted at Srinakharinwirot University in Bangkok, Thailand, found participants who took NONS after COVID-19 exposure were 75% less likely to become infected when compared to the control group, yielding a statistically significant reduction in infection rate. The study was carried out during an...

Phase 3 Clinical Trial Confirms SaNOtize’s Treatment is 99% Effective Against COVID-19

On February 10, 2022 0 Comment

SaNOtize and Glenmark Pharmaceuticals Limited has announced on February 09, 2022: Phase 3 trial reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours Treatment also demonstrated, in the high-risk group (n=218), a greater proportion of patients who achieved a combination of clinical and virological cure, based on the WHO Progression Scale Median time to virological cure was 4 days in the treatment group, 8 days in the placebo group (p < 0.05). A Phase 3 clinical trial was...